Correlation between gut microbiota and the development of Graves’ disease: A prospective study

Deng, Yuanyuan; Wang, J; Xie, Guijiao; Zou, Guilin; Li, Shanshan; Zhang, Jie; Cai, Wei; Xu, Jibin

doi:10.1016/j.isci.2023.107188

Cited by 5 publications

(8 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is still debate regarding this bacterium. Deng et al suggested an increased abundance of Veillonella in GD patients (Deng et al, 2023), while this study aligns with previous reports indicating lower levels of Veillonella in GD patients(Table 3).…”

Section: Discussionsupporting

confidence: 93%

“…SCFAs can serve as an energy source for epithelial cells, maintain intestinal barrier integrity, and reduce gut permeability and circulating lipopolysaccharide levels (Koh et al, 2016). Su et al (2020) and a prospective study (Deng et al, 2023) both found reduced levels of propionate and butyrate in GD patients, thereby corroborating the notion that decreased SCFAs production in GD patients promotes disease occurrence and progression.…”

Section: Discussionmentioning

confidence: 83%

“…This discovery was validated in a multicenter study conducted by Biscarini et al (2023). Moreover, a prospective study similarly indicated distinctive features in the gut microbiota of GD patients, which might be linked to imbalances in the immune system and gut microbiota (Deng et al, 2023). These studies provide compelling evidence for a causal relationship between gut microbiota and GD.…”

Section: Introductionmentioning

confidence: 83%

“…Most studies indicate a significant decrease in gut microbiota abundance in GD patients compared to healthy individuals, this aligns with our findings. For instance, Deng et al analyzed the gut microbiota of Graves' disease patients and controls and found that GD patients exhibited lower gut bacterial diversity (Deng et al, 2023). However, some studies have reported no significant changes in gut microbiota abundance and diversity in GD patients (Yang et al, 2019;Chang et al, 2021), which requires further investigation for confirmation.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Bacteroidaceae, Bacteroides, and Veillonella: emerging protectors against Graves’ disease

Liu,

Li,

Cai

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

BackgroundGraves’ disease (GD) is the most common cause of hyperthyroidism, and its pathogenesis remains incompletely elucidated. Numerous studies have implicated the gut microbiota in the development of thyroid disorders. This study employs Mendelian randomization analysis to investigate the characteristics of gut microbiota in GD patients, aiming to offer novel insights into the etiology and treatment of Graves’ disease.MethodsTwo-sample Mendelian randomization (MR) analysis was employed to assess the causal relationship between Graves’ disease and the gut microbiota composition. Gut microbiota data were sourced from the international consortium MiBioGen, while Graves’ disease data were obtained from FINNGEN. Eligible single nucleotide polymorphisms (SNPs) were selected as instrumental variables. Multiple analysis methods, including inverse variance-weighted (IVW), MR-Egger regression, weighted median, weighted mode, and MR-RAPS, were utilized. Sensitivity analyses were conducted employing MR-Egger intercept test, Cochran’s Q test, and leave-one-out analysis as quality control measures.ResultsThe Mendelian randomization study conducted in a European population revealed a decreased risk of Graves’ disease associated with Bacteroidaceae (Odds ratio (OR) [95% confidence interval (CI)]: 0.89 [0.89 ~ 0.90], adjusted P value: <0.001), Bacteroides (OR: [95% CI]: 0.555 [0.437 ~ 0.706], adjusted P value: <0.001), and Veillonella (OR [95% CI]: 0.632 [0.492 ~ 0.811], adjusted P value: 0.016). No significant evidence of heterogeneity, or horizontal pleiotropy was detected. Furthermore, the preliminary MR analysis identified 13 bacterial species including Eubacterium brachy group and Family XIII AD3011 group, exhibiting significant associations with Graves’ disease onset, suggesting potential causal effects.ConclusionA causal relationship exists between gut microbiota and Graves’ disease. Bacteroidaceae, Bacteroides, and Veillonella emerge as protective factors against Graves’ disease development. Prospective probiotic supplementation may offer a novel avenue for adjunctive treatment in the management of Graves’ disease in the future.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 83%

Section: Introductionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Bacteroidaceae, Bacteroides, and Veillonella: emerging protectors against Graves’ disease

Liu,

Li,

Cai

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Recent investigations have elucidated marked gut microbiota dysbiosis in GD patients, characterized by reduced diversity and skewed microbial profiles ( Su et al., 2020 ; Jiang et al., 2021 ). Nonetheless, certain studies yield conflicting data concerning the genera levels ( Zhao et al., 2022 ; Deng et al., 2023 ). Notably, a majority of these investigations rely on clustering sequences based on operational taxonomic units (OTUs) — an approach that has faced scrutiny ( Edgar, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

Alteration in gut microbiota is associated with immune imbalance in Graves’ disease

Liu,

Tang,

Feng

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

BackgroundGraves’ disease (GD), characterized by immune aberration, is associated with gut dysbiosis. Despite the growing interest, substantial evidence detailing the precise impact of gut microbiota on GD’s autoimmune processes remains exceedingly rare.ObjectiveThis study was designed to investigate the influence of gut microbiota on immune dysregulation in GD.MethodsIt encompassed 52 GD patients and 45 healthy controls (HCs), employing flow cytometry and enzyme-linked immunosorbent assay to examine lymphocyte and cytokine profiles, alongside lipopolysaccharide (LPS) levels. Gut microbiota profiles and metabolic features were assessed using 16S rRNA gene sequencing and targeted metabolomics.ResultsOur observations revealed a disturbed B-cell distribution and elevated LPS and pro-inflammatory cytokines in GD patients compared to HCs. Significant differences in gut microbiota composition and a marked deficit in short-chain fatty acid (SCFA)-producing bacteria, including ASV263(Bacteroides), ASV1451(Dialister), and ASV503(Coprococcus), were observed in GD patients. These specific bacteria and SCFAs showed correlations with thyroid autoantibodies, B-cell subsets, and cytokine levels. In vitro studies further showed that LPS notably caused B-cell subsets imbalance, reducing conventional memory B cells while increasing naïve B cells. Additionally, acetate combined with propionate and butyrate showcased immunoregulatory functions, diminishing cytokine production in LPS-stimulated cells.ConclusionOverall, our results highlight the role of gut dysbiosis in contributing to immune dysregulation in GD by affecting lymphocyte status and cytokine production.

show abstract

The relationship between the gut microbiota and thyroid disorders

Ludgate,

Masetti,

Soares

2024

Nat Rev Endocrinol

View full text Add to dashboard Cite

Correlation between gut microbiota and the development of Graves’ disease: A prospective study

Cited by 5 publications

References 69 publications

Bacteroidaceae, Bacteroides, and Veillonella: emerging protectors against Graves’ disease

Bacteroidaceae, Bacteroides, and Veillonella: emerging protectors against Graves’ disease

Alteration in gut microbiota is associated with immune imbalance in Graves’ disease

The relationship between the gut microbiota and thyroid disorders

Contact Info

Product

Resources

About